Le Mali medical · 2026
[Value Of Bone Scintigraphy To Mdp-Tc 99m In The Management Of Prostate Cancer At The Institute Of Radioisotopes Of Niamey].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Moussa Issoufou Djibrillou, Ousmane Manzo Maman Sani, Boka Tounga Yahouza, Adamou Seydou Hamadou, Oumarou Karimoune Mossi, Amadou Soumana
Аннотация
INTRODUCTION: Prostate cancer is a real public health problem. Studies have shown that 95% of deaths secondary to this cancer are due to metastases. The earlier metastases are diagnosed, the better the chances of survival.
OBJECTIVE: Analyze the results and show the contribution of bone scintigraphy in the management of prostate cancer in Niger.
METHODS: This was a retrospective descriptive and analytical study over a period of 8 years from February 09, 2014 to March 13, 2022 at the Department of Nuclear Medicine of the Institute of Radioisotopes of Niamey of patients who had undergone a bone scan as part of the management of prostate cancer.
RESULTS: The frequency of requesting bone scintigraphy concerning the prostate was 7%. The average age of our patients was 67.6 years with extremes ranging from 50 to 90 years. The most represented age group was 60 to 70 years. During the period of our study, bone scintigraphy was indicated in 93% of our patients as part of an initial assessment of prostate cancer. Urologists and oncologists were the main prescribers of this examination in 43.8% and 35.4% respectively. In our study, abnormal PSA > 20 ng/ml was predominant in 69.2%. Bone scintigraphy was abnormal in 72% (n=69) of cases. Bone lesions predominated on the axial + appendicular skeleton in 75.3% (n=52) with the most spinal injuries in 54%.
CONCLUSION: Bone scintigraphy plays a diagnostic, therapeutic and prognostic role in prostatic cancer.
OBJECTIVE: Analyze the results and show the contribution of bone scintigraphy in the management of prostate cancer in Niger.
METHODS: This was a retrospective descriptive and analytical study over a period of 8 years from February 09, 2014 to March 13, 2022 at the Department of Nuclear Medicine of the Institute of Radioisotopes of Niamey of patients who had undergone a bone scan as part of the management of prostate cancer.
RESULTS: The frequency of requesting bone scintigraphy concerning the prostate was 7%. The average age of our patients was 67.6 years with extremes ranging from 50 to 90 years. The most represented age group was 60 to 70 years. During the period of our study, bone scintigraphy was indicated in 93% of our patients as part of an initial assessment of prostate cancer. Urologists and oncologists were the main prescribers of this examination in 43.8% and 35.4% respectively. In our study, abnormal PSA > 20 ng/ml was predominant in 69.2%. Bone scintigraphy was abnormal in 72% (n=69) of cases. Bone lesions predominated on the axial + appendicular skeleton in 75.3% (n=52) with the most spinal injuries in 54%.
CONCLUSION: Bone scintigraphy plays a diagnostic, therapeutic and prognostic role in prostatic cancer.